Aperio Group LLC lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 13.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 23,407 shares of the biopharmaceutical company’s stock after purchasing an additional 2,695 shares during the quarter. Aperio Group LLC’s holdings in Alnylam Pharmaceuticals were worth $2,049,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently added to or reduced their stakes in ALNY. Point72 Asset Management L.P. boosted its position in shares of Alnylam Pharmaceuticals by 49.4% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,356,408 shares of the biopharmaceutical company’s stock valued at $133,593,000 after purchasing an additional 448,362 shares during the period. American Century Companies Inc. acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $42,128,000. Baillie Gifford & Co. boosted its position in shares of Alnylam Pharmaceuticals by 10.4% in the 2nd quarter. Baillie Gifford & Co. now owns 4,231,881 shares of the biopharmaceutical company’s stock valued at $416,798,000 after purchasing an additional 397,668 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its position in shares of Alnylam Pharmaceuticals by 333.0% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 302,695 shares of the biopharmaceutical company’s stock valued at $29,812,000 after purchasing an additional 232,782 shares during the period. Finally, Federated Investors Inc. PA boosted its position in shares of Alnylam Pharmaceuticals by 50.4% in the 2nd quarter. Federated Investors Inc. PA now owns 603,250 shares of the biopharmaceutical company’s stock valued at $59,414,000 after purchasing an additional 202,207 shares during the period. Institutional investors and hedge funds own 90.37% of the company’s stock.
In other Alnylam Pharmaceuticals news, COO Yvonne Greenstreet sold 2,500 shares of the firm’s stock in a transaction dated Thursday, August 30th. The stock was sold at an average price of $120.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief operating officer now directly owns 1,916 shares in the company, valued at approximately $229,920. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.30% of the company’s stock.
Shares of NASDAQ ALNY opened at $73.04 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $71.85 and a one year high of $153.99. The stock has a market cap of $8.69 billion, a price-to-earnings ratio of -13.48 and a beta of 2.54. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.22 and a quick ratio of 13.22.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.02) by ($0.41). Alnylam Pharmaceuticals had a negative return on equity of 38.09% and a negative net margin of 533.52%. The business had revenue of $2.07 million for the quarter, compared to analyst estimates of $22.66 million. During the same quarter in the previous year, the business posted ($1.34) earnings per share. The company’s revenue was down 87.9% compared to the same quarter last year. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.28 EPS for the current year.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
See Also: Preferred Stock
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.